Dätwyler (DAE) H1 2024 earnings summary

Executive summary

• Revenue declined 5.0% year-over-year to CHF 572.5 million, mainly due to weak markets and healthcare destocking, with a CHF 7.5 million drop in COVID vaccine component sales.

• EBIT increased by 11.6% to CHF 67.5 million, with EBIT margin up 180 bps to 11.8% despite lower sales.

• Net result rose 20.2% to CHF 38.6 million; net result per share increased to CHF 2.27 from CHF 1.89.

• Profitability improved through cost optimization, price adjustments, and lower energy costs.

• New CEO and CFO appointed in H1 2024, both with extensive industry experience.

Financial highlights

• Gross profit margin improved to 22.3% from 20.4% year-over-year.

• EBITDA grew 9.2% to CHF 109.6 million, with EBITDA margin at 19.1%.

• Free cash flow increased to CHF 65.8 million, mainly due to lower CapEx.

• Capital expenditures decreased to CHF 19.7 million from CHF 29.2 million.

• Net debt at CHF 508.8 million, improved by CHF 8 million year-over-year.

Outlook and guidance

• No significant change expected in market environment for H2 2024, with weak demand and healthcare destocking persisting.

• Full-year 2024 revenue expected in line with or slightly below prior year; EBIT margin expected above previous year.

• Midterm EBIT margin guidance of 18%-21% remains, targeted within 3-5 years, contingent on Healthcare project execution.

• Long-term growth expected as market demand normalizes and innovation projects commercialize.